1971 - Fellow of the American Association for the Advancement of Science (AAAS)
Henry S. Friedman mostly deals with Internal medicine, Glioma, Cancer research, Chemotherapy and Surgery. His Internal medicine research incorporates elements of Gastroenterology and Oncology. His Glioma study incorporates themes from Survival rate, Pathology, ATRX, Alkyltransferase and Telomerase reverse transcriptase.
His work carried out in the field of Cancer research brings together such families of science as Mutation, Tyrosine kinase, Gene duplication and Epidermal growth factor receptor. As part of one scientific family, Henry S. Friedman deals mainly with the area of Chemotherapy, narrowing it down to issues related to the Toxicity, and often Complication and Pharmacokinetics. He works mostly in the field of Surgery, limiting it down to topics relating to Clinical trial and, in certain cases, Randomized controlled trial.
Henry S. Friedman mainly focuses on Internal medicine, Glioma, Chemotherapy, Oncology and Surgery. His work on Bevacizumab, Temozolomide and Phases of clinical research as part of general Internal medicine research is frequently linked to Irinotecan, thereby connecting diverse disciplines of science. His study explores the link between Glioma and topics such as Pathology that cross with problems in Astrocytoma.
The Chemotherapy study combines topics in areas such as Medulloblastoma, Radiation therapy, Toxicity and Pharmacology. His Oncology research includes elements of Cancer and Glioblastoma. Many of his studies on Surgery apply to Clinical trial as well.
His main research concerns Internal medicine, Oncology, Glioma, Bevacizumab and Glioblastoma. His is doing research in Temozolomide, Chemotherapy, Adverse effect, Chemotherapy regimen and Cancer, both of which are found in Internal medicine. He interconnects Gastroenterology, Stem cell and Immunology in the investigation of issues within Chemotherapy.
His research in Oncology intersects with topics in Phases of clinical research, Dose escalation, Brain tumor, Recurrent glioblastoma and Radiation therapy. His Glioma study is related to the wider topic of Cancer research. Bevacizumab is a primary field of his research addressed under Surgery.
The scientist’s investigation covers issues in Internal medicine, Glioma, Oncology, Cancer research and Bevacizumab. His Glioma research is multidisciplinary, incorporating perspectives in Oncolytic virus, IDH1, Pathology, Stem cell and Regulation of gene expression. His biological study spans a wide range of topics, including Cancer, Phases of clinical research, Survival rate, Recurrent glioblastoma and Radiation therapy.
His Cancer research research integrates issues from Epidermal growth factor receptor, Mutation, ATRX, Telomerase and Epigenetics. His Bevacizumab study is focused on Surgery in general. His Chemotherapy study frequently draws connections between related disciplines such as Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
IDH1 and IDH2 Mutations in Gliomas
Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon.
The New England Journal of Medicine (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen.
Journal of Clinical Oncology (2009)
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello.
Journal of Clinical Oncology (2007)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela;Zachary J. Reitman;Yuchen Jiao;Chetan Bettegowda.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell.
Clinical Cancer Research (2007)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W K A Yung;R E Albright;J Olson;R Fredericks.
British Journal of Cancer (2000)
Temozolomide and treatment of malignant glioma.
Henry S. Friedman;Tracy Kerby;Hilary Calvert.
Clinical Cancer Research (2000)
Postoperative Chemotherapy and Delayed Radiation in Children Less Than Three Years of Age With Malignant Brain Tumors
Patricia K. Duffner;Marc E. Horowitz;Jeffrey P. Krischer;Henry S. Friedman.
The New England Journal of Medicine (1993)
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
W. K.Alfred Yung;Michael D. Prados;Ricardo Yaya-Tur;Steven S. Rosenfeld.
Journal of Clinical Oncology (1999)
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell.
Journal of Clinical Oncology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: